What the study found
Several new analogs of AOH1996, a small-molecule inhibitor of proliferating cell nuclear antigen (PCNA, a protein involved in DNA replication and repair), showed antiproliferative activity in cancer cell cultures. The parent compound AOH1996 was still the most potent in the tests reported.
Why the authors say this matters
The authors conclude that some of these analogs, especially 2b and 3b, can serve as useful lead scaffolds for further optimization and experimental validation. They also note that several active compounds were predicted to inhibit P-glycoprotein, suggesting potential relevance for overcoming multidrug resistance.
What the researchers tested
The researchers synthesized a series of AOH1996-based structural analogs using structure-activity relationship (SAR) and scaffold-hopping strategies. They tested the compounds in MCF-7 breast cancer and U87 glioblastoma cell lines with the MTT assay, and they also used ADMET predictions to estimate drug-likeness, absorption, and other properties.
What worked and what didn't
AOH1996 reduced cell viability below 30% at 10 μM and showed the strongest cytotoxicity. Compounds 1f, 2b, 3b, 3c, and 3d were also active, reducing MCF-7 viability by 60–70% and U87 viability to 30–40% at 10 μM. The SAR analysis reported that electron-withdrawing or moderately lipophilic substituents on the amide side chain and aromatic extensions on the triazole ring improved potency, while bulky or strongly electron-donating groups reduced activity.
What to keep in mind
The available summary is limited to cell-culture testing and computational predictions, so it does not describe in vivo results or clinical testing. The abstract also notes predicted limitations for many derivatives, including high plasma protein binding, short predicted half-lives, and potential cardiotoxicity.
Key points
- AOH1996 was the most potent compound in the reported cell-culture tests.
- Five analogs, including 2b and 3b, showed significant antiproliferative activity.
- The study tested compounds in MCF-7 breast cancer and U87 glioblastoma cells using the MTT assay.
- SAR findings linked higher potency to electron-withdrawing or moderately lipophilic substituents and aromatic extensions on the triazole ring.
- ADMET predictions suggested favorable drug-likeness for most derivatives but also possible limits such as short half-life and cardiotoxicity.
Disclosure
- Research title:
- AOH1996 analogs showed varied anticancer activity in cancer cell cultures
- Authors:
- Simona Jonušienė, Agnė Janonienė, Mantas Jonušis, Adas Darinskas, D. Sokol
- Institutions:
- National Cancer Institute, Vilnius University, Vilnius University, Vilnius University, Vilnius University
- Publication date:
- 2026-03-05
- OpenAlex record:
- View
Get the weekly research newsletter
Stay current with scholarly research without reading academic papers — one filtered digest, every Friday.